Geoffrey Greene to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Geoffrey Greene has written about Drug Resistance, Neoplasm.
Connection Strength
0.881
-
Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Mol Cancer Ther. 2021 01; 20(1):11-25.
Score: 0.147
-
The NF-?B Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers. Mol Cancer Res. 2020 07; 18(7):1018-1027.
Score: 0.141
-
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. 2018 11 29; 7.
Score: 0.129
-
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat Rev Cancer. 2018 06; 18(6):377-388.
Score: 0.124
-
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013 Dec; 45(12):1439-45.
Score: 0.091
-
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393.
Score: 0.086
-
Selective pressure of endocrine therapy activates the integrated stress response through NF?B signaling in a subpopulation of ER positive breast cancer cells. Breast Cancer Res. 2022 03 09; 24(1):19.
Score: 0.040
-
The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Mol Pharmacol. 2020 07; 98(1):24-37.
Score: 0.036
-
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Rep. 2019 10 22; 29(4):889-903.e10.
Score: 0.034
-
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. Clin Cancer Res. 2018 07 15; 24(14):3433-3446.
Score: 0.031
-
Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013 Apr 09; 2:e00499.
Score: 0.022